Recently, Jin et al.40 proposed dual inhibition of BMI1 and EZH2 as a more efficient therapeutics against glioma than BMI1 (using PTC596) or EZH2 (using EPZ6438) inhibition alone. The gene discussed is EZH2; the disease is central nervous system cancer.